Heron Therapeutics, Inc.
HRTX· Nasdaq
HRTXHeron Therapeutics, Inc.
Filed Mar 12, 2024 · 10-K · 72 days after period end · 0000950170-24-029951
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $34.23M | $30.03M | $20.66M | $20.61M |
| Net Income | -$10.72M | -$19.87M | -$54.65M | -$62.28M |
| EPS Diluted | — | — |
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
| — |
| -$0.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Mar 12, 2024 · 72 d after period end
